POPULATION PHARMACOKINETIC MODELS - EFFECT OF EXPLICIT VERSUS ASSUMEDCONSTANT SERUM CONCENTRATION ASSAY ERROR PATTERNS UPON PARAMETER VALUES OF GENTAMICIN IN INFANTS ON AND OFF EXTRACORPOREAL MEMBRANE-OXYGENATION
Wf. Dodge et al., POPULATION PHARMACOKINETIC MODELS - EFFECT OF EXPLICIT VERSUS ASSUMEDCONSTANT SERUM CONCENTRATION ASSAY ERROR PATTERNS UPON PARAMETER VALUES OF GENTAMICIN IN INFANTS ON AND OFF EXTRACORPOREAL MEMBRANE-OXYGENATION, Therapeutic drug monitoring, 16(6), 1994, pp. 552-559
Prior authors had hypothesized (but not clearly found) an increased ap
parent volume of distribution (V-d) for gentamicin in neonates undergo
ing extracorporeal membrane oxygenation (ECMO). We chose to study the
question in our own clinical setting. To develop population pharmacoki
netic models of the drug, we used the nonparametric expectation and ma
ximization population modeling method and data from 11 neonates who re
ceived gentamicin on ECMO, including 6 infants who received gentamicin
both on and off ECMO for severe respiratory failure. We found an incr
eased V-d for gentamicin on ECMO and attributed much of the difference
from prior investigations to our use of an explicitly determined labo
ratory assay error pattern for the measured serum concentrations rathe
r than using constant weighting of the serum revel data points. For si
x infants, while on ECMO their median V-d was 0.748 L/kg compared with
a median V-d of 0.471 L/kg after ECMO was discontinued. The median cl
earance of gentamicin in the six infants while undergoing ECMO was 0.2
39 L/h compared with 0.350 Lih after ECMO was discontinued. The median
half-time (T-1/2) was 9.24 h while on ECMO compared with 3.87 h when
off ECMO. We conclude that while undergoing ECMO, neonates have a high
er volume of distribution for gentamicin, a lower clearance, and a muc
h longer half-life. Based on these results, for attainment of the desi
red peak-and-trough plasma gentamicin concentrations for infants under
going ECMO (i.e., 5-8 and <2.0 mu g/ml, respectively), we now recommen
d a loading dose of similar to 4.3 mg/kg of gentamicin and a maintenan
ce dose of similar to 3.7 mg/kg to be given at dosing intervals of 18-
24 h, followed by monitoring of serum concentrations and appropriate d
ose adjustments thereafter. To attain alternative goals, the model pro
vides different loading and maintenance doses.